{"groups":[{"description":"8 milligrams/kilogram (mg/kg) of ramucirumab (IMC-1121B) was administered by intravenous (IV) infusion on Days 1 and 15 in combination with 80 milligrams/square meter (mg/m²) paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"FG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"FG001","title":"Placebo Plus Paclitaxel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"9"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"11"}],"type":"Withdrawal of consent without follow-up"}],"milestones":[{"achievements":[{"comment":"Participant was included in ramucirumab (IMC-1121B)/paclitaxel treatment arm (safety population).","groupId":"FG000","numSubjects":"330"},{"comment":"Participant was included in the placebo/paclitaxel treatment arm (intent-to-treat (ITT) population).","groupId":"FG001","numSubjects":"335"}],"comment":"One participant randomized to placebo/paclitaxel arm but received ramucirumab (IMC-1121B) in error.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"327"},{"groupId":"FG001","numSubjects":"329"}],"type":"Received Any Treatment (Safety Pop)"},{"achievements":[{"groupId":"FG000","numSubjects":"316"},{"groupId":"FG001","numSubjects":"315"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"20"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Completers include participants that discontinued study drugs either due to progressive disease (PD), due to an adverse event or died due to any cause, but not necessarily had any survival-FU assessment done."}